ResearchSafe

Dutasteride (Dutasteride (Avodart))

Category: Hair Growth. Status: FDA Approved (BPH) / Off-label hair loss.

A dual 5-alpha reductase inhibitor (type I and II) that blocks ~90% of DHT production, compared to finasteride's ~70%. Increasingly prescribed off-label for androgenetic alopecia when finasteride alone is insufficient.

How it works

Inhibits both type I and type II 5-alpha reductase isoenzymes, reducing serum DHT by ~90% and scalp DHT by ~50%. Prevents miniaturization of androgen-sensitive hair follicles in the vertex and frontal scalp.

Key facts

  • Molecular weight: 528.53 Da
  • Half-life: ~5 weeks (extremely long)
  • Bioavailability: ~60% oral
  • Storage: Room temperature. Do not handle if pregnant (teratogenic risk).

Dosing overview

  • Typical dose: 0.5 mg
  • Frequency: Daily
  • Duration: 6-12 months minimum for visible results
  • Route: Oral capsule

Reported benefits

  • Superior DHT suppression vs finasteride
  • Hair regrowth and thickening
  • Reduced hair miniaturization
  • Prostate volume reduction
  • Effective for diffuse thinning

Possible side effects

  • Sexual side effects (5-7%)
  • Decreased libido
  • Gynecomastia (rare)
  • Depression (rare)
  • Post-finasteride syndrome (controversial)

Research

  • Dutasteride vs finasteride for AGA (2022): Dutasteride 0.5mg produced 12% greater hair count improvement than finasteride 1mg at 24 weeks in vertex AGA (Phase III).
  • Long-term dutasteride safety for hair loss (2021): 5-year follow-up showed sustained hair maintenance in 90% of patients with sexual side effects occurring in <5% and resolving on discontinuation.

Compare Dutasteride

Community discussions about Dutasteride

Research and educational reference only. Not medical advice.